Skip to content

Efficacy and safety of halometasone cream to treat chronic generalized eczema and the effects of halometasone cream on serum cortisol levels

Efficacy and safety of halometasone cream to treat chronic generalized eczema and the effects of halometasone cream on serum cortisol levels

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPH-17012348
Enrollment
Unknown
Registered
2017-08-12
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eczema

Interventions

A a lesion area of 30%-40%:halometasone cream with a daily dose of 15g for 7-14 days,
B a lesion area of 40%~50%:halometasone cream with a daily dose of 20g for 7-14 days,
B a lesion area of 50%~60%:halometasone cream with a daily dose of 30g for 7-14 days,

Sponsors

Department of Dermatology, Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. with a confirmed diagnosis of chronic generalized eczema according to the diagnostic criteria; 2. the disease severity was at least moderate (Investigators Global Assessment score = 3); 3. the skin lesions were at multiple sites and affected 30% to 60% of the total body surface area; 4. the target lesions were at the limbs or trunk and showed a diameter of 2 cm to10 cm; 5. adult patients aged 18 to 80 years; 6. voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. skin lesions were accompanied with infection of viruses, bacteria, and/or fungi; 2. the eczema were on the face and skin-folding areas; 3. systemic use of glucocorticoid and/or immunosuppressant, and/or ultraviolet light therapy within 4 weeks before the enrollment interview; 4. local use of glucocorticoid and/or oral use of antihistamines within two weeks before the enrollment interview; 5. with severe disease in the liver, kidney, and/or blood; 6. with autoimmune diseases, chronic serious infection, diabetes, mental diseases, substance abuse, and/or alcoholic; 7. with the malignant tumor or other serious diseases that may compromise the accuracy of efficacy evaluation for the study drug; 8. any other condition that the investigators believed could interfere in the study; 9. pregnant, breast-feeding, or plan to become pregnant during the study period; 10. allergic to the study drugs; 11. failed to follow the study protocol.

Design outcomes

Primary

MeasureTime frame
EASI;adverse event;Efficacy index;serum cortisol (COR);

Countries

China

Contacts

Public ContactXu Wei

Department of Dermatology, Beijing Friendship Hospital, Capital Medical University

2403649155@qq.com+86 18611015100

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026